| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 28,704.5 | 24,617.13 | 23,366.55 | 24,557.95 | 22,737.95 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 28,704.5 | 24,617.13 | 23,366.55 | 24,557.95 | 22,737.95 |
Other Operating Income | 297.37 | 238.25 | 88.94 | 216.68 | 360.55 |
Other Income | 557.38 | 290.59 | 320.35 | 3,195.42 | 86.2 |
Total Income | 29,559.25 | 25,145.97 | 23,775.84 | 27,970.05 | 23,184.7 |
Total Expenditure | 23,367.89 | 21,148.41 | 19,227.94 | 19,496.58 | 18,315.2 |
PBIDT | 6,191.36 | 3,997.56 | 4,547.9 | 8,473.47 | 4,869.5 |
Interest | 289.71 | 140.48 | 48.64 | 74.49 | 159.77 |
PBDT | 5,901.65 | 3,857.08 | 4,499.26 | 8,398.98 | 4,709.73 |
Depreciation | 1,521.66 | 1,244.58 | 1,126.52 | 1,055.38 | 966.71 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 1,777.54 | 1,071.48 | 662.82 | 2,321.82 | 956.95 |
Deferred Tax | -566.52 | -386.63 | 62.81 | -312.05 | -43.44 |
Reported Profit After Tax | 3,168.97 | 1,927.65 | 2,647.11 | 5,333.83 | 2,829.51 |
Minority Interest After NP | -4 | 0.15 | -1.04 | -1.02 | -1.46 |
Net Profit after Minority Interest | 3,172.97 | 1,927.5 | 2,648.15 | 5,334.85 | 2,830.97 |
Extra-ordinary Items | -114 | 0 | -100.44 | 1,924.7 | -19.45 |
Adjusted Profit After Extra-ordinary item | 3,286.97 | 1,927.5 | 2,748.59 | 3,410.15 | 2,850.42 |
EPS (Unit Curr.) | 54.16 | 32.9 | 45.19 | 91.04 | 48.32 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 450 | 300 | 900 | 400 | 300 |
Equity | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 21.56 | 16.23 | 19.46 | 34.5 | 21.41 |
PBDTM(%) | 20.56 | 15.66 | 19.25 | 34.2 | 20.71 |
PATM(%) | 11.03 | 7.83 | 11.32 | 21.71 | 12.44 |
Pazopanib Tablets, 200 mg, is an alternative equivalent of Votrient Tablets, 200 mg, manufactured by Novartis and used for the treatment of specific types of cancer.
Aurobindo Pharma stated that once commercialised, the drugs will be manufactured at Partner's facilities and marketed by both parties.
Here are some of the stocks that may see significant price movement today: Suzlon Energy, Aurobindo Pharma, Coal India, etc.
On June 17, 2022, Aurobindo purchased a 51% share in GLS Pharma from entrepreneur Suresh Pathak and his family members.
Here are some of the stocks that may see significant price movement today: IREDA, Garden Reach Shipbuilders, Nazara Tech, etc.
The approval was based on a supplemental Abbreviated New Drug Application (sANDA) for an alternate facility for manufacturing and testing.
Aurobindo Pharma Ltd has gained a total of 79% in the last one year, and almost 45% since the beginning of the year.
Eugia Steriles, a 100% subsidiary of Eugia Pharma Specialities and a step down arm of Aurobindo Pharma, operates the new plant.
"Our China plant is expected to be commercialised in Q3 FY25, with a ramp-up beginning in Q4 FY25," Subramanian said during an analyst call.
An OAI status indicates that the USFDA's inspection discovered significant concerns that require regulatory or administrative action.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
